In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk adults aged 50-59 this week. Read more here.

The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of ...

In this article, we are going to look at where Moderna, Inc. (NASDAQ ... and a supportive regulatory environment, Goldman Sachs referred to it as an “undervalued opportunity.” ...

The major U.S. equity indexes were lower midday Monday, as the Trump administration showed no signs of pulling back from ...

US stocks saw choppy trading on Tuesday (April 15) as investors digested a new round of first-quarter earnings reports and ...

The S&P 500 and the Nasdaq Composite today posted their worst quarterly performances since 2022, as uncertainty around the Trump administration’s economic agenda roiled U.S. equity markets in the ...

The Eurozone March CPI rose +2.2% y/y, right on expectations and the slowest pace of increase in 5 months. The March core CPI rose +2.4% y/y, weaker than expectations of +2.5% y/y and the smallest ...

Citing solid fundamentals, improved clinical outcomes, and a supportive regulatory environment, Goldman Sachs referred to ... from its last price of $79.92. Moderna, Inc. (NASDAQ:MRNA) is a ...